Delaware Clinical Trials Report — June 2026

For Delaware residents considering participation in clinical research, June 2026 presents a crucial window of opportunity, particularly for those interested in studies nearing their conclusion. A total of 14 clinical trials across the state are slated to close within the next 90 days, meaning time is running out to enroll. This includes 5 studies that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition. If you've been thinking about participating, now is the time to explore these options before they close.

Urgent Opportunities: Trials Nearing Enrollment Deadlines

Individuals living with certain health conditions should act quickly to explore trials with impending deadlines. Research focusing on various conditions, from oncology to chronic diseases, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (2 trials)
• Advanced malignant neoplasm
• Blindness
• Aging
• Anxiety disorders and symptoms
• Arthritis
• Advanced solid tumor
• Advanced breast cancer
• Cardiovascular risk factor
• Chronic granulomatous disease (CGD)

These studies represent diverse areas of medical inquiry, and your participation could be vital in advancing understanding and treatment for these conditions. Remember, 5 of these closing trials are also open to healthy volunteers, providing a direct path to contribute to general health research.

New Research Horizons: Sleep, Women's Health, and More

This month, Delaware welcomes 3 new clinical trials, a slight decrease from the 4 trials that opened in May 2026. These new studies bring fresh opportunities for participation, particularly in the areas of sleep quality and women's health. One notable new trial is focusing on a plant-based intervention for sleep, offering a unique opportunity for healthy adults.

Spotlight on Sleep Quality: A Notable New Study

One of the most interesting new opportunities is NCT07669766, titled "Somato® (Phytomelatonin) Versus Synthetic Melatonin and Placebo on Sleep Quality." Sponsored by Nutraland USA, Inc., this study aims to enroll 244 participants to examine the effects of a plant-based phytomelatonin supplement compared to synthetic melatonin and a placebo. The research employs a randomized, double-blind, placebo-controlled, three-arm clinical trial design, a gold standard for evaluating new interventions. If you experience suboptimal sleep quality, this study in Newark could be a valuable option to explore a novel approach to improving rest.

Expanding Options in Women's Health

The other new trials this month primarily focus on various aspects of women's health, offering crucial research opportunities for conditions that impact many individuals. These new studies address a range of gynecological concerns, including:

• Abnormal uterine bleeding, unspecified
• Adenomyosis of uterus
• Adnexal diseases
• Chronic pelvic pain
• Endometriosis
• Endometritis
• Fibroid uterus
• Menorrhagia
• Minimally invasive surgical procedures

These trials represent important steps forward in understanding and treating conditions that significantly affect quality of life for many women. One of these new trials is specifically designed for female participants only, ensuring focused research on these conditions.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 3 new trials launched this month, 1 is actively seeking healthy volunteers. This new opportunity is the "Somato® (Phytomelatonin) Versus Synthetic Melatonin and Placebo on Sleep Quality" study (NCT07669766), which is open to adults with suboptimal sleep quality. Statewide, a total of 30 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and contributing to broader health knowledge.

Delaware's Research Footprint: Where to Find Trials

Delaware's clinical research landscape continues to be active, with 289 clinical trials currently recruiting across 15 cities and 120 research sites statewide. This broad distribution ensures that residents in various regions of Delaware have access to cutting-edge research. This month, the new research initiatives are concentrated in two key areas:

• Newark (2 new trials)
• Wilmington (1 new trial)

While the new trials are focused in these urban centers, the overall number of sites and cities recruiting across the state means that opportunities are available beyond these specific locations. Whether you live in a major metropolitan area or a smaller community, there's a good chance a research site is accessible to you.

Who Can Participate? Demographics and Sponsors

Clinical trials in Delaware are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 3 include older adults, ensuring that research benefits this important demographic. While no new trials this month include children or are male-only, 1 new trial is female-only, reflecting the focus on women's health conditions. This demographic breakdown ensures that research addresses the needs of diverse populations within the state.

Academic institutions and industry sponsors both play vital roles in Delaware's research ecosystem. This month's new trials are sponsored by:

• Christiana Care Health Services (1 trial)
• Nutraland USA, Inc. (1 trial)
• University of Delaware (1 trial)

These sponsors represent a mix of academic and "OTHER" (often institutional or foundation-funded) research, with Nutraland USA, Inc. representing industry involvement. This collaboration between different types of research organizations helps drive innovation and expand the range of studies available to Delaware residents.

As we move through June, the focus will remain on the ongoing enrollment in these studies, particularly those nearing their close, and the exploration of new treatments and interventions for a broad spectrum of health challenges across Delaware.